Tuesday, September 23, 2014 11:39:45 AM
The researchers in India will be planning and executing a comprehensive research program which would not be possible for several months to a year in Canada due to the waiting period for obtaining a Canadian R and D license. They will also prepare protocols for clinical trials which can be conducted immediately in India and subsequently in Canada after Verde obtains its R and D license. The company plans to develop specific, custom formulations and novel delivery mechanisms for cannabinoid and THC based drugs for a variety of ailments such as chronic pain, inflammation, migraines, seizures related to epilepsy, nausea associated with cancer treatment, and numerous others.
"This new Research and Development Program with a focus on developing custom formulations for specific medical issues will firmly place Verde on the cutting edge of cannabinoid and THC technology in treating illness, and our association with our new Indian partner will enable us to become a clearing house for research into new applications for marijuana based treatments of a variety of illnesses. The Verde brand will be synonymous with innovation into natural based remedies for a variety of debilitating illnesses." stated Mr. Sangha.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM